|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS10009 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:100-500 IF=1:100-500 |
| CAS編號 | |
| 抗體名 | Anti-NMDA-NR1/NR1/NMDAR1 |
| 克隆性 | |
| 靶點 | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human NMDAR1 N-terminus |
產(chǎn)品訂購信息：
英文名稱 Anti-NMDA-NR1/NR1/NMDAR1
中文名稱 天冬氨酸受體抗體費用
別 名 NMDA-NR1; N-Methyl-d-Asprtate receptor 1; GRIN1; NMDA1; NMDAR1; NR1; Glutamate [NMDA] receptor subunit zeta 1; Glutamate receptor ionotropic N methyl D aspartate 1; Grin 1; Grin1; N methyl D aspartate receptor channel; N-methyl-D-aspartate receptor; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDA 1; NMDA NR1; NMDA R1; NMDA receptor 1; NMDA1; NMDAR 1; NMDAR; Nmdar1; NR 1; NR1; NMDZ1_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 細(xì)胞膜受體
蛋白分子量 predicted molecular weight: 103kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human NMDAR1 N-terminus
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
天冬氨酸受體抗體費用 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Neuronal Marker
NMDA receptor subtypes of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. NMDAR1 plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission and is involved in the cell surface targeting of NMDA receptors.Function : NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors.Subunit : Forms heteromeric channel of a zeta subunit (GRIN1), a epsilon subunit (GRIN2A, GRIN2B, GRIN2C or GRIN2D) and a third subunit (GRIN3A or GRIN3B); disulfide-linked. Found in a complex with GRIN2A or GRIN2B, GRIN3A or GRIN3B and PPP2CB. Interacts with DLG4 and MPDZ. Interacts with LRFN1 and LRFN2. Interacts with MYZAP.Subcellular Location : Cell membrane; Multi-pass membrane protein. Cell junction, synapse, postsynaptic cell membrane. Cell junction, synapse, postsynaptic cell membrane, postsynaptic density. Note=Enriched in post-synaptic plasma membrane and post-synaptic densities.Post-translational modifications : NMDA is probably regulated by C-terminal phosphorylation of an isoform of NR1 by PKC. Dephosphorylated on Ser-897 probably by protein phosphatase 2A (PPP2CB). Its phosphorylated state is influenced by the formation of the NMDAR-PPP2CB complex and the NMDAR channel activity.DISEASE : Defects in GRIN1 are the cause of mental retardation autosomal dominant type 8 (MRD8) [MIM:614254]. Mental retardation is characterized by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period.Similarity : Belongs to the glutamate-gated ion channel (TC 1.A.10.1) family. NR1/GRIN1 subfamily.Database links : UniProtKB/Swiss-Prot: Q05586.1神經(jīng)細(xì)胞標(biāo)志物(NMDAR1)N-甲基-D-天門冬氨酸受體(NMDAR)是興奮性氨基酸受體亞型之一，是由NMDAR1與不同的NMDAR2亞基組成的異聚體。近年實驗研究發(fā)現(xiàn)，許多NMDAR拮抗藥均具有活性，表明NMDAR在痛覺傳遞中具有重要作用，這為新型藥的研究開發(fā)提供了新的作用靶點。
JNK (Rat c-Jun N-terminal kinases,JNK) ELISA Kit 大鼠c-Jun氨基末端激酶Multi-class antibodies規(guī)格： 48T
Anti-STAT4 信號轉(zhuǎn)導(dǎo)和轉(zhuǎn)錄激活因子4抗體Multi-class antibodies規(guī)格： 0.1ml
Rhesus antibody Rh Goat Anti-human IgG/Bio 生物素標(biāo)記的羊抗人IgG 規(guī)格 0.1ml
Tn- I ELISA Kit 大鼠肌鈣蛋白Ⅰ 96T
NMDA epsilon 2 英文名稱： 谷酸受體NMDAζ2抗體 0.2ml
phospho-B-Raf (Thr401) 英文名稱： 磷酸化B-Raf抗體 0.1ml
Anti-STAT4 信號轉(zhuǎn)導(dǎo)和轉(zhuǎn)錄激活因子4抗體Multi-class antibodies規(guī)格： 0.1ml
Kiss-1(Metastasis-suppressor KiSS-1 precursor) 轉(zhuǎn)移抑制基因(抗原)Multi-class antibodies規(guī)格： 0.5mg
Anti-CD26 CD26抗體Multi-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh PAK4 p21激活激酶4抗體 規(guī)格 0.1ml
SULT1E1 Kit Human 人 SULT1E1 ELISA配對抗體 ELISA
TLX2 英文名稱： T淋巴細(xì)胞同源蛋白2抗體 0.2ml
CD24 英文名稱： CD24抗體 0.1ml
Anti-CD26 CD26抗體Multi-class antibodies規(guī)格： 0.2ml
NKB ELISA Kit(Ret) 大鼠神經(jīng)肽BMulti-class antibodies規(guī)格： 96T
Anti-Bdkrb2/B2R/FITC 熒光素標(biāo)記緩激肽B2受體抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh ERK1/MAPK3 原活化蛋白激酶3抗體 規(guī)格 0.1ml
TARC/CCL17(Human thymus activation regulated chemokine) ELISA Kit 人胸腺活化調(diào)節(jié)趨化因子 96T
MX2 英文名稱： 干擾素誘導(dǎo)GTP結(jié)合蛋白MX2抗體 0.2ml
Adenylate kinase 2 英文名稱： 腺苷酸激酶2抗體 0.2ml
Anti-Bdkrb2/B2R/FITC 熒光素標(biāo)記緩激肽B2受體抗體IgGMulti-class antibodies規(guī)格： 0.2ml
FASLG Protein Human 重組人 Fas Ligand / FASLG / CD95L 蛋白 (His 標(biāo)簽)
CNE-2 低分化細(xì)胞
ICOS Others Mouse 小鼠 ICOS / AILIM / CD278 人細(xì)胞裂解液 (陽性對照)
BxPC-3人原位*腺癌細(xì)胞 BxPC-3 in situ pancreatic adenocarcinoma cells 1640+10% FBS
小鼠細(xì)胞(分泌促生長激素分泌激素);AtT-20
人成纖維細(xì)胞( HCF) ( 5×105 ) GC-1, 鼠精原細(xì)胞 Mouse
CL-0456TM4(正常小鼠Sertoli細(xì)胞)5×106cells/瓶×2
SIGIRR Others Human 人 SIGIRR / TIR8 人細(xì)胞裂解液 (陽性對照)
人膀胱基質(zhì)成纖維細(xì)胞RNAHBdSF miRNA5 μg
T24細(xì)胞，人膀胱移行細(xì)胞癌細(xì)胞 大鼠細(xì)胞(wistar 大鼠),CBRH7919細(xì)胞 RN-c, 大鼠皮質(zhì)神經(jīng)元
Ishikawa(人細(xì)胞) 5×106cells/瓶×2
hPC-PL-c 人類胎盤周細(xì)胞(hPC-PL) 500,000cells 小鼠巨噬細(xì)胞MMa
天冬氨酸受體抗體費用 FASLG Protein Human 重組人 Fas Ligand / FASLG / CD95L 蛋白 (His 標(biāo)簽)
CNE-2 低分化細(xì)胞
ICOS Others Mouse 小鼠 ICOS / AILIM / CD278 人細(xì)胞裂解液 (陽性對照)
BxPC-3人原位*腺癌細(xì)胞 BxPC-3 in situ pancreatic adenocarcinoma cells 1640+10% FBS
小鼠細(xì)胞(分泌促生長激素分泌激素);AtT-20
人成纖維細(xì)胞( HCF) ( 5×105 ) GC-1, 鼠精原細(xì)胞 Mouse
抗體的生物素化標(biāo)記實驗要點：
1. 天冬氨酸受體抗體費用 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）天冬氨酸受體抗體費用 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴(kuò)散試驗來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力?？贵w的特異性高,它的識別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。
|
|
|
|
|
